Physician profile
Jacquelyn Dosal
NPI 1114159837
$8,967.02
in general payments reported to CMS, 2019-2025
32 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $302 · 2021: $571 · 2022: $705 · 2023: $1,371 · 2024: $5,021 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $2,256 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,914 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,255.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,913.75 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,461.63 | 2023-2024 | Spevigo |
| Revance Therapeutics, INC. | $938.18 | 2024-2025 | Daxxify |
| Abbvie INC. | $752.95 | 2022-2024 | Rinvoq, Botox, Skyrizi |
| Allergan, INC. | $544.18 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $275.43 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $273.58 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $185.70 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $154.63 | 2019-2024 | Winlevi |
| Pfizer INC. | $144.52 | 2020-2021 | |
| Dermira, INC. | $136.01 | 2019-2020 | |
| Almirall LLC | $102.46 | 2019-2025 | Klisyri, Seysara |
| Genzyme Corporation | $98.35 | 2020-2023 | |
| Incyte Corporation | $98.00 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $97.09 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.39 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $76.66 | 2019 | |
| Vyne Pharmaceuticals INC. | $75.47 | 2020-2021 | |
| Janssen Biotech, INC. | $55.90 | 2020-2022 | |
| Lilly USA, LLC | $54.10 | 2020-2021 | |
| Ucb, INC. | $45.09 | 2021-2023 | Cimzia |
| Epi Health, LLC | $43.21 | 2019-2020 | |
| Journey Medical Corporation | $35.41 | 2019 | |
| Amgen INC. | $31.59 | 2023 | Otezla |
| Biofrontera INC. | $31.33 | 2019-2021 | |
| Celgene Corporation | $26.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.79 | 2023 | |
| Strata Skin Sciences, INC. | $24.02 | 2019-2021 | |
| Covidien LP | $22.01 | 2019 | |
| Promius Pharma LLC | $20.25 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.24 | 2025 | |
| Aclaris Therapeutics, INC. | $17.47 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Dosal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.